摘要
直肠是胃肠间质瘤的第三常见部位,其临床病理学特征、生物学行为和解剖部位使其诊治具有特殊性。好发于直肠中下段且术后局部复发率偏高,都是直肠GIST治疗的难点。伊马替尼的围手术期治疗增加了手术切除率并降低了复发率,5 cm以下的直肠GIST靶向治疗联合手术切除治疗效果较好。目前,国内外尚缺少直肠GIST的诊疗规范,未来还需要更多的前瞻性多中心研究进一步探讨并得出结论。
Rectum is the third most common site GISTs originise from. The management of rectal GISTs holds characteristics and difficulty owing to biology and anatomical location. They tending to occur in lower rectum with relatively high local recurrence rate. The application of peri-operational imatinib increase the resectability of tumor and lower recurrence rate. For rectal GIST with diameter of less than 5 cm, imatinib combined surgical resection can achieve a good therapeutic effect. At present, there is still lack of standard of diagnosis and treatment for rectal GIST worldwide. More prospective multicenter studies are needed for better understanding and management of this special entity.
作者
张信华
Zhang Xinhua(Department of Gastrointinal Surgery,the First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China)
出处
《中华结直肠疾病电子杂志》
2019年第3期227-230,共4页
Chinese Journal of Colorectal Diseases(Electronic Edition)
基金
广东省科技计划(No.2016A020213002)
关键词
直肠
胃肠间质瘤
伊马替尼
Rectum
Gastrointestinal stromal tumors
Imatinib